• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutics and Clinical Risk Management >Efficacy and safety of Ginkgo biloba extract as an “add-on” treatment to metformin for patients with metabolic syndrome: a pilot clinical study
【24h】

Efficacy and safety of Ginkgo biloba extract as an “add-on” treatment to metformin for patients with metabolic syndrome: a pilot clinical study

机译：银杏叶提取物作为二甲双胍对代谢综合征患者的“附加”治疗的功效和安全性：一项临床试验研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and aim: Ginkgo biloba (GKB) extract has shown to be beneficial in experimental models of metabolic and inflammatory disorders such as diabetes and metabolic syndrome (MTS). The objective of this pilot clinical study was to evaluate the effects of GKB extract as an “add-on” treatment with metformin (Met) in MTS patients. Patients and methods: We performed a randomized, placebo-controlled, double-blinded clinical study in subjects with MTS. Forty patients completed the 90-day clinical trial and were randomly allocated to administer either GKB extract (120?mg capsule/day) or placebo (120?mg starch/day) as an add-on treatment with their currently used doses of Met for 90?days. During the study, body mass index (BMI), waist circumference (WC), serum leptin, glycated hemoglobin (HbA1c), fasting serum glucose (FSG), insulin, insulin resistance (IR), visceral adiposity index (VAI), lipid profile, and the inflammatory markers high sensitive C-reactive protein (hsCRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were evaluated. Results: GKB extract significantly decreases HbA1c, FSG and insulin levels, IR, BMI, WC, VAI, serum leptin, and the inflammatory markers compared to baseline values. Simultaneously, GKB did not negatively affect the functions of the liver, kidney, and hematopoietic system. Conclusion: The use of GKB extract as an adjuvant with Met was effective in improving the outcome of patients with MTS.
机译：背景与目的：银杏叶提取物（GKB）已证明对代谢和炎症性疾病（例如糖尿病和代谢综合征（MTS））的实验模型有益。这项初步临床研究的目的是评估GKB提取物作为二甲双胍（Met）的“附加”治疗在MTS患者中的作用。患者和方法：我们对患有MTS的受试者进行了一项随机，安慰剂对照，双盲的临床研究。 40名患者完成了为期90天的临床试验，并随机分配GKB提取物（120？mg胶囊/天）或安慰剂（120？mg淀粉/天）作为他们目前使用的Met剂量的附加治疗药物。 90天。在研究过程中，体重指数（BMI），腰围（WC），血清瘦素，糖化血红蛋白（HbA1c），空腹血糖（FSG），胰岛素，胰岛素抵抗（IR），内脏脂肪指数（VAI），脂质分布，并评估了炎症标记物高敏C反应蛋白（hsCRP），肿瘤坏死因子-α（TNF-α）和白介素6（IL-6）。结果：与基线值相比，GKB提取物显着降低了HbA1c，FSG和胰岛素水平，IR，BMI，WC，VAI，血清瘦素和炎性标志物。同时，GKB对肝，肾和造血系统的功能没有负面影响。结论：GKB提取物作为Met的佐剂可有效改善MTS患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号